
FDA AEMS E2B(R3) Cutover: 2026 Migration Runbook
A 2026 FDA AEMS E2B(R3) cutover runbook covering the October 1 deadline, applicability, R2 transformation risks, ESG NextGen testing, acknowledgements, validation, and hypercare.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

A 2026 FDA AEMS E2B(R3) cutover runbook covering the October 1 deadline, applicability, R2 transformation risks, ESG NextGen testing, acknowledgements, validation, and hypercare.

Review 10 years of FDA 483 patterns and EMA reports. Learn the four core inspection question clusters and the specific evidence required for compliance.
© 2026 IntuitionLabs. All rights reserved.